AU2021267650A1 - Detection of complement proteins - Google Patents

Detection of complement proteins Download PDF

Info

Publication number
AU2021267650A1
AU2021267650A1 AU2021267650A AU2021267650A AU2021267650A1 AU 2021267650 A1 AU2021267650 A1 AU 2021267650A1 AU 2021267650 A AU2021267650 A AU 2021267650A AU 2021267650 A AU2021267650 A AU 2021267650A AU 2021267650 A1 AU2021267650 A1 AU 2021267650A1
Authority
AU
Australia
Prior art keywords
complement
seq
protein
subject
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021267650A
Other languages
English (en)
Inventor
Paul Bishop
Simon Clark
Richard Unwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Complement Therapeutics Ltd
Original Assignee
Complement Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Complement Therapeutics Ltd filed Critical Complement Therapeutics Ltd
Publication of AU2021267650A1 publication Critical patent/AU2021267650A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2021267650A 2020-05-07 2021-05-06 Detection of complement proteins Pending AU2021267650A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2006789.8 2020-05-07
GBGB2006789.8A GB202006789D0 (en) 2020-05-07 2020-05-07 Detection of complement proteins
PCT/EP2021/062077 WO2021224430A1 (en) 2020-05-07 2021-05-06 Detection of complement proteins

Publications (1)

Publication Number Publication Date
AU2021267650A1 true AU2021267650A1 (en) 2023-01-19

Family

ID=71134867

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021267650A Pending AU2021267650A1 (en) 2020-05-07 2021-05-06 Detection of complement proteins

Country Status (8)

Country Link
US (1) US20230400470A1 (enExample)
EP (1) EP4147057A1 (enExample)
JP (1) JP7849304B2 (enExample)
CN (1) CN115997127A (enExample)
AU (1) AU2021267650A1 (enExample)
CA (1) CA3177760A1 (enExample)
GB (1) GB202006789D0 (enExample)
WO (1) WO2021224430A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
GB202203627D0 (en) * 2022-03-16 2022-04-27 Univ Manchester Agents for treating complement-related disorders
JP2026501750A (ja) 2023-01-05 2026-01-16 コンプリメント・セラピューティクス・リミテッド 補体疾患を処置するための薬剤および方法
WO2025083211A1 (en) * 2023-10-20 2025-04-24 Institut National de la Santé et de la Recherche Médicale Use of factor h for the treatment of dementia
LU103244B1 (en) 2024-02-14 2025-08-14 Univ Hamburg Eppendorf Uke Deletion of the mouse homolog of human FHR1 (FHRE) protects ApoE-/- mice from atherosclerosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005211063A (ja) 2004-01-30 2005-08-11 Junko Maekuroshima ブレンドノニ茶
WO2008005455A2 (en) 2006-07-03 2008-01-10 The Johns Hopkins University Peptide antibody depletion and its application to mass spectrometry sample preparation
WO2009059321A2 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
GB0815576D0 (en) 2008-08-28 2008-10-01 Lucas & Co Analysis of glycated proteins
WO2016068616A1 (ko) 2014-10-29 2016-05-06 차의과학대학교 산학협력단 C3 또는 c1r 보체를 분비하는 태반 유래 세포 및 이를 포함하는 조성물
GB201709222D0 (en) 2017-06-09 2017-07-26 Univ Manchester C3b Inactivating Polypeptide
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
KR102775717B1 (ko) 2018-03-13 2025-03-06 암젠 인크 질량 분광 분석을 위한 폴리펩티드의 순차적 소화
WO2019215330A1 (en) 2018-05-10 2019-11-14 The University Of Manchester Methods for assessing macular degeneration

Also Published As

Publication number Publication date
CA3177760A1 (en) 2021-11-11
GB202006789D0 (en) 2020-06-24
CN115997127A (zh) 2023-04-21
WO2021224430A1 (en) 2021-11-11
US20230400470A1 (en) 2023-12-14
EP4147057A1 (en) 2023-03-15
JP7849304B2 (ja) 2026-04-21
JP2023524130A (ja) 2023-06-08

Similar Documents

Publication Publication Date Title
US20230400470A1 (en) Detection of complement proteins
Stamellou et al. IgA nephropathy
JP7135039B2 (ja) 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP5100901B2 (ja) 加齢性黄斑変性を処置および診断するための方法および試薬
Martínez-Barricarte et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation
JP7467355B2 (ja) 黄斑変性症を評価するための方法
US20230384322A1 (en) Complementome assay
CN102150046B (zh) 组织蛋白酶c的用途
DaSilva et al. Cleavage of osteopontin by matrix metalloproteinase-12 modulates experimental autoimmune encephalomyelitis disease in C57BL/6 mice
CN101160412A (zh) 治疗和诊断年龄相关性黄斑变性的方法和试剂
WO2023175099A1 (en) Agents for treating complement-related disorders
AU2022279580A1 (en) Inhibitory nucleic acids for factor h family proteins
WO2019241158A1 (en) Compositions and methods for treating inflammatory diseases
Le Cam-Duchez et al. Rare genotypes of protein Z gene are a risk factor for premature myocardial infarction but not protein Z plasma level
EP3491383A1 (en) Salivary abeta42 levels as prognostic indicators for alzheimer's disease
EP2873739B1 (en) Diagnosis of syndromic obesity
EP3115784A1 (en) Polypeptide marker for analysis, diagnosis and therapy of eye-related diseases
Daher et al. Moderate Iron Overload in Humans
Dommett Structural and functional studies of mannose binding lectin (MBL) and the lectin pathway of complement in children with cancer
Ansari Analysis of biomarkers for complex human diseases